Fundraising Fox
/Companies
Sign in

Neuroone Medical Technologies

NASDAQ: NMTC

Eden Prairie, US · Delaware corporation

Find your way into Neuroone Medical Technologies

352 people in our graph share verified history with the Neuroone Medical Technologies team — schools, employers, funds. One of them is your warm intro.

Hanson S. Gifford, IIIunlockedknows Steve Mertens · together at Nuvaira (overlapped)
×2knows the team · via Cardiovascular Systems, Inc.
×8knows the team · via Robert Half International
knows the team · via St. Jude Medical

NeuroOne Medical Technologies develops and commercializes implantable neurological devices, including cortical strip and grid electrodes, depth electrodes, and ablation systems for brain monitoring and treatment, with distribution arrangements through third-party partners. The company is advancing its portfolio toward profitability through regulatory clearances and product commercialization while managing substantial going-concern uncertainties.

Biotech

Founders & leadership

RM
Ronald McClurgExecutive
MCMark Christianson
Mark ChristiansonExecutive
SMSteve Mertens
Steve MertensExecutiveSteve Mertens is an executive officer at NeuroOne Medical Technologies, bringing experience in product development, manufacturing, and commercialization across research-driven organizations and startup environments.
CVChristopher Volker
Christopher VolkerExecutiveChristopher Volker has held executive positions in medical device and healthcare companies, with experience in general management, corporate development, and mergers and acquisitions spanning multiple functional areas including strategy, quality, and reimbursement. He has led numerous transactions in the healthcare and technology sectors.
DR
David RosaChief Executive Officer, President and Director
TB
Thomas BachinskiNamed on SEC filing
AS
Amer SamadNamed on SEC filing

Board

JS
Jeffrey S. MathiesenBoard director
PB
Paul BuckmanBoard director
EA
Edward AndrleBoard director

Reported raises · per SEC filings

Form D private placements

$21.2M disclosed across 10 of 11 rounds · 2017–2024

▶$276KraisedAug 2024 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey S. MathiesenDirector
  • Ronald McClurgExecutive Officer
  • Paul BuckmanDirector
  • David A. RosaExecutive Officer, Director
  • Edward AndrleDirector
  • Mark ChristiansonExecutive Officer
  • Steve MertensExecutive Officer
  • Christopher VolkerExecutive Officer
Offering amount
$276K
Amount sold
$276K
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.5MraisedJan 2021 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward AndrleDirector
  • Ronald McClurgExecutive Officer
  • Paul BuckmanDirector
  • Steve MertensExecutive Officer
  • Mark ChristiansonExecutive Officer
  • David A. RosaExecutive Officer, Director
  • Jeffrey S. MathiesenDirector
Offering amount
$12.5M
Amount sold
$12.5M
Sales commissions
$1M
Proceeds to insiders
$1.4M
Placement agents
The Benchmark Company, LLC
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$135KraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward AndrleDirector
  • Jeffrey S. MathiesenDirector
  • David A. RosaExecutive Officer, Director
  • Paul BuckmanDirector
  • Mark ChristiansonExecutive Officer
  • Steve MertensExecutive Officer
Offering amount
$135K
Amount sold
$135K
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedMay 2020 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark ChristiansonExecutive Officer
  • Steve MertensExecutive Officer
  • Jeffrey S. MathiesenDirector
  • David A. RosaExecutive Officer, Director
  • Paul BuckmanDirector
  • Edward AndrleDirector
Offering amount
$6M
Amount sold
$2.5M
Minimum investment
$25K
Sales commissions
$360K
Proceeds to insiders
$943K
Placement agents
Paulson Investment Company
First sale
Apr 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$255KraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David A. RosaExecutive Officer, Director
  • Mark ChristiansonExecutive Officer
  • Jeffrey S. MathiesenDirector
  • Suraj KaliaDirector
  • Paul BuckmanDirector
  • Steve MertensExecutive Officer
Offering amount
$1M
Amount sold
$255K
Minimum investment
$25K
First sale
Oct 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedNov 2019 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steve MertensExecutive Officer
  • Jeffrey S. MathiesenDirector
  • Suraj KaliaDirector
  • Paul BuckmanDirector
  • Mark ChristiansonExecutive Officer
  • David A. RosaExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.3M
Minimum investment
$25K
Sales commissions
$240K
Proceeds to insiders
$976K
Placement agents
Paulson Investment Company
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedFeb 2019 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas BachinskiExecutive Officer
  • Suraj KaliaDirector
  • David A. RosaExecutive Officer, Director
  • Jeffrey S. MathiesenDirector
  • Mark ChristiansonExecutive Officer
  • Paul BuckmanDirector
Offering amount
$10M
Amount sold
$1.5M
Sales commissions
$90.2K
Proceeds to insiders
$823.1K
Placement agents
Mohammad Jainal Bhuiyan
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$992.5KraisedFeb 2019 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul BuckmanDirector
  • Jeffrey S. MathiesenDirector
  • David A. RosaExecutive Officer, Director
  • Thomas BachinskiExecutive Officer
  • Suraj KaliaDirector
  • Mark ChristiansonExecutive Officer
Offering amount
$10M
Amount sold
$992.5K
Sales commissions
$1.2M
Proceeds to insiders
$823.1K
Placement agents
Mark Finckle, Mohammad Jainal Bhuiyan
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Neuroone Medical Technologies do?
NeuroOne Medical Technologies develops and commercializes implantable neurological devices, including cortical strip and grid electrodes, depth electrodes, and ablation systems for brain monitoring and treatment, with distribution arrangements through third-party partners. The company is advancing its portfolio toward profitability through regulatory clearances and product commercialization while managing substantial going-concern uncertainties.
How much funding has Neuroone Medical Technologies raised?
Neuroone Medical Technologies has disclosed $21.2M raised across 10 of its 11 known rounds.
Where is Neuroone Medical Technologies headquartered?
Neuroone Medical Technologies is headquartered in Eden Prairie, US.